Amarin Corp. announced a new position that will help build the biopharmaceutical company’s revenue growth as its first FDA-approved product is available by prescription.
Mark W. Salyer is Amarin’s first chief commercial officer. He was an executive vice president and general manager at Teva Pharmaceuticals, where he grew revenue exceeding $1 billion in more than 10 years.
“Mark brings a strong track record of success, coupled with valuable experience and proven leadership, to our management team to help drive our anticipated expansion,” Amarin CEO and President John F. Thero said. “We expect Mark’s driven, people-oriented, hands-on approach to work well with our existing commercial organization to help build on our growth. Amarin remains on track to reach record product revenues of $165 to $175 million in 2017.”
Salyer said he is “impressed by the opportunity presented by Vascepa,” the Bedminster company’s first Food & Drug Administration-approved product, which helps reduce triglycerides in the blood.
Salyer also comes on as outcomes from a trial into whether four grams a day of EPA Vascepa can reduce cardiovascular events in patients. The REDUCE-IT results are expected in the second or third quarter of next year. The name stands for Reduction of Cardiovascular Events with Icosapent Ethyl — Intervention Trial.
“I am delighted to join Amarin at this exciting time,” Salyer said. “Amarin’s success to date is undisputable and the future holds substantial opportunities for even greater growth, in particular with the potentially game-changing REDUCE-IT cardiovascular trial results forthcoming. The opportunity to lead the commercial team at a company on the cusp of an anticipated new frontier in preventive cardiovascular therapy was too compelling an opportunity to not seize, especially given the staggering mortality, morbidity and costs of care among the affected patient population.”
